Ultragenyx And Mereo BioPharma To Complete Phase 3 UX143 Trials In Osteogenesis Imperfecta By Year-End; Data Monitoring Committee Supports Continued Study With Safety Profile

Author: Benzinga Newsdesk | July 09, 2025 04:08pm

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) and Mereo BioPharma Group plc (NASDAQ:MREO), today announced that the randomized, placebo-controlled Phase 3 portion of the Orbit study evaluating UX143 (setrusumab) in pediatric and young adult patients with osteogenesis imperfecta (OI) is progressing toward a final analysis consistent with the original plan, around the end of the year.

The Data Monitoring Committee (DMC) met and informed the company that UX143 demonstrates an acceptable safety profile and the company should continue the study to the final analysis.

Posted In: MREO RARE